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Abstract
Background—Rotaviruses are the major cause of severe dehydrating diarrhea in children 
throughout the world. Enzyme immunoassays (EIA) have been the standard method for detection 
of rotavirus in stool specimens since the 1980s. The World Health Organization (WHO) Rotavirus 
Surveillance Network has proposed including three EIA kits in the WHO-GSM (Global 
Management System/Système Mondial de Gestion ) catalogue for easy procurement of EIA kits 
by participating rotavirus surveillance network laboratories.
Objectives—In this study, we conducted a comparative analysis of 3 commercially available 
enzyme immunoassay kits: PremierTM Rotaclone® (Meridian Bioscience, Inc.), ProSpecTTM 
(Oxoid, Ltd.) and RIDASCREEN® (R-biopharm AG) for rotavirus diagnostics.
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Study design—Using reverse-transcriptase-PCR (RT-PCR) as the gold standard, the 3 EIA kits 
were evaluated by testing a stool panel consisting of 56 rotavirus-positive and 54 rotavirus 
negative samples.
Results—The sensitivities of the PremierTM Rotaclone®, ProSpecTTM and RIDASCREEN® kits 
were 76.8%, 75% and 82.1% respectively, but did not differ significantly. The specificity of all the 
3 kits was 100%. The use of RT-PCR as a gold standard lowered the observed sensitivity of all 3 
EIA kits but helps to reduce equivocal results that can be seen when another EIA or other non-
molecular methods are used as the reference assay in comparison studies.
Conclusion—Our study found that all three kits are suitable for use by rotavirus surveillance 
programs.
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Background
Group A rotaviruses are the leading cause of acute gastroenteritis (AGE) in infants and 
young children worldwide1, 2. Enzyme immunoassays (EIAs) offer a simple, rapid, and 
sensitive method for routine laboratory detection of rotavirus antigen in stool specimens3. 
Commercial EIA kits have been available since the 1980s and evaluations of these kits have 
been performed3-5, but a comparison of current generation EIA kits has not been done. The 
Rotavirus Surveillance Laboratory, Centers for Disease Control and Prevention, Atlanta, 
Georgia, USA is the Global Reference Laboratory for the World Health Organization 
(WHO) Rotavirus Surveillance Network.
Objectives
To assist the WHO in recommending the best commercially available kits for rotavirus 
detection to laboratories that participate in the global network, we conducted a comparative 
analysis study of 3 EIA kits in order to determine if these 3 kits meet performance criteria 
required for inclusion in the WHO-GSM (Global Management System/Système Mondial de 
Gestion) catalogue to facilitate reagent procurement by network surveillance laboratories. 
The EIA kits included in this study were: 1) the PremierTM Rotaclone® (Meridian 
Bioscience, Inc., Cincinnati OH, USA); 2) the ProSpecTTM Rotavirus Microplate Assay 
(Oxoid, Ltd., Basingstoke, Hampshire, UK); and the 3) RIDASCREEN® Rotavirus (R-
Biopharm AG, Darmstadt, Germany). All 3 kits use a solid-phase sandwich EIA format. The 
PremierTM Rotaclone® kit is the only multi-well EIA kit approved by the U.S. Food and 
Drug Administration (FDA) for in vitro diagnostic (IVD) use. It uses monoclonal antibodies 
raised against rotavirus structural protein VP6. The ProSpecTTM Rotavirus Microplate 
Assay EIA kit is a replacement kit for the widely-used rotavirus IDEIATM Rotavirus EIA 
(Dako Diagnostics Ltd., Ely UK), which was discontinued in March 2009. It uses polyclonal 
capture and detector antibodies raised against rotavirus structural proteins. The 
RIDASCREEN® Rotavirus EIA kit uses monoclonal antibodies raised against rotavirus 
structural protein VP6. In 2010, RIDASCREEN® was reformulated to incorporate a 
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biotinylated detector antibody and streptavidin-conjugated peroxidase. The analytical 
performance of these kits has not been compared directly.
Study Design
Stool samples from AGE cases were selected from domestic and international surveillance 
samples received by the CDC for genotyping of rotavirus strains. All the samples selected 
for this study were tested for the presence of rotavirus VP4 and VP7 and/or VP6 genes using 
reverse transcription-PCR (RT-PCR)6-8. Fifty-six rotavirus-positive samples and 54 
rotavirus-negative samples were selected for this study. All 110 samples were tested for 
rotavirus antigen according to manufacturers’ instructions for each kit. Three operators 
performed all tests, for a total of 3 replicates per sample. EIA plates were read on an MRXe 
ELISA plate reader (Dynex Technologies, Chantilly, VA USA). A sample was considered to 
test positive by a kit if the optical density (OD) values for 2 or 3 replicates were above the 
calculated cut-off value for that kit. The analytical sensitivity, specificity, positive predictive 
value (PPV) and negative predictive value (NPV) were calculated for each kit. Statistical 
analyses were performed by using Prism Version 5.02 Software for Windows (GraphPad 
Software, Inc., La Jolla, CA). Testing results were analyzed by chi-square test. OD values 
were compared by Kruskal-Wallis test, and pairwise comparisons mean OD values from 
each kit were performed using Dunn’s Multiple Comparison test.
Results
The results of testing 110 samples in triplicate by each kit are shown (Table 1). For each of 
the 3 kits, all EIA-positive samples had tested as rotavirus-positive by RT-PCR for VP4 and 
VP7 or VP6 and all EIA-negative samples had tested negative by RT-PCR. However, some 
RT-PCR positive samples tested negative by EIA, ranging from 10 for RIDASCREEN® 
Rotavirus to 14 for ProSpecTTM. Using RT-PCR as the gold standard, the performance 
characteristics of the kits were: PremierTM Rotaclone® EIA, 76.8% sensitivity, 100% 
specificity, PPV = 100% , NPV = 80.6%; ProSpecTTM EIA, 75% sensitivity, 100% 
specificity, PPV = 100%, NPV = 79.4%; and, RIDASCREEN® Rotavirus, 82.1% 
sensitivity, 100% specificity, PPV = 100%, NPV = 84.4%. When the sample testing results 
of the 3 kits, expressed as positives and negatives, were analyzed by chi-square test (Table 
1), the results obtained by each kit were not found to differ significantly. Distribution plots 
of OD values for the 3 kits (n = 330; Figure 1) showed that the distribution for the 
PremierTM Rotaclone® and ProSpecTTM Rotavirus kits were similar, with each plot skewed 
to the right. For both assays, numerous data points lay within 0.05 OD units on either side of 
the cut-off value (Rotaclone®, n=23; ProSpecT™, n=20). In contrast, for the 
RIDASCREEN® kit, OD values were bimodally distributed, with one large peak on the left 
side of the graph containing all the negative values, and a broad peak on the right side 
containing the majority of the positive OD values. Only 1 data point lay within 0.05 OD 
units on either side of the cut-off value. The OD values from the 3 kits were found to differ 
significantly, and this difference was observed when all data points were analyzed (p = 
0.0131), when positive OD values only were analyzed (p < 0.001), and when negative OD 
values only were analyzed (p < 0.001). Pairwise comparisons showed that the OD values 
from the RIDASCREEN® kit differed significantly (p < 0.05) from those of the ProSpecT™ 
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kit but did not differ significantly from those of the Rotaclone® kit. The OD values 
generated by the PremierTM Rotaclone® and ProSpecTTM kits did not differ significantly. 
We found the PremierTM Rotaclone® EIA to have 76.8% sensitivity and 100% specificity 
compared with 100% sensitivity and 92% specificity as reported by its manufacturer, 
Meridian Bioscience, Inc. and 100% sensitivity and 99-100% specificity as reported in 
published studies.3, 5. The ProSpecTTM Rotavirus EIA kit exhibited 75% sensitivity and 
100% specificity in this study as compared with 100% sensitivity and 99.2% specificity as 
reported by Oxoid, Ltd. RIDASCREEN® EIA showed 82.1% sensitivity and 100% 
specificity as compared to 98.4% sensitivity and 100% specificity as reported by R-
biopharm AG. The differences between the sensitivity and specificity values that we found 
and those reported by the manufacturers and others results from using different gold 
standard methods. We used RT-PCR as a gold standard whereas Meridian Bioscience 
compared PremierTM Rotaclone® EIA results to electron microscopy (EM) and other studies 
used a reference EIAs3, 5. Oxoid compared ProSpecTTM Rotavirus EIA results to EM and a 
commercial EIA kit, and R-Biopharm compared RIDASCREEN® EIA results to other 
certified EIA kit results. The use of the more sensitive RT-PCR technique9 for establishing 
the gold-standard lowers the observed sensitivity of all 3 EIA kits but helps to reduce 
equivocal results that can be seen when another EIA or other methods are used as the 
reference assay in comparison studies 3, 5 _ENREF_3. In May 2010, Oxoid Ltd. changed the 
method used to calculate the cut-off value of ProSpecTTM Rotavirus kit by specifying that 
cut-off limit should be calculated by adding 0.2 absorbance units to the negative control 
value; previously 0.1 absorbance units were added. When the ProSpecTTM Rotavirus results 
from this study were reinterpreted using a cut-off value calculated using the original method, 
the sensitivity increased to from 75 to 87.5%, surpassing sensitivity attained by the 
RIDASCREEN® kit. Oxoid Ltd. changed the method of calculating the cut-off limit for the 
ProSpecTTM kit so that its performance would be equivalent to that of the IDEIATM kit, 
which it replaced. However, this change appears to have reduced the sensitivity of the 
ProSpecTTM Rotavirus kit.
Conclusions
In this study, we evaluated and compared 3 EIA kits, PremierTM Rotaclone®, ProSpecTTM 
Rotavirus, and RIDASCREEN® Rotavirus for detection of rotavirus antigen in stool 
samples. Testing of the kits against a stringent gold standard showed them to have 
comparable sensitivity and specificity, thus, all 3 kits are suitable for use in rotavirus 
surveillance programs worldwide.
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Frequency distributions of OD values for the PremierTM Rotaclone®, ProSpecTTM 
Rotavirus, and RIDACREEN® Rotavirus EIA kits. Bins (logical ranges) were set at every 
0.05 OD units. The vertical dashed line on each graph indicates the assay cut-off value. The 
y-axis of the bottom graph has been condensed between 100 and 180 to maintain the 
visibility of the shorter data bars.
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Table 1
Comparison of Rotavirus Detection Results by Premiere™ Rotaclone®, ProSpecT ™ Rotavirus and 



























Total 56 54 110
a
Results obtained by each kit were not found to differ significantly (p = 0.8483, Chi-square = 0.3291, df = 2)
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